August 9, 2011, CCM - Grandhope Biotech Co., Ltd. (Grandhope) launched Initial Public Offerings (IPO) in Shenzhen Growth Enterprise Market (GEM) on July 7, 2011. It plans to invest about USD38 million in the construction of national regenerative medical implants engineering laboratory, high-tech industrialization of sterile biological membrane, market expansion and maintenance of the core business, according to CCM’s August Issue of Industrial Biotechnology China News.
Grandhope has become the sixth listed biomedical enterprises inGuangzhou , China
The raised fund for Grandhope's IPO will be mainly applied to these investments: construction of regenerative medical implants national engineering laboratory, high-tech industrialization of sterile biological membrane, market expansion and maintenance of the core business. Mr. Zhu especially explained the strategy of the first three projects: the construction of the laboratory, which costs Grandhope USD5.9 million, would lead the company to strengthen the core competitiveness in the high-tech field. In order to get more profit and market share, Grandhope invested USD3.1 million in high-tech industrialization of sterile biological membrane, which would promote the adjustment of the product structure. The market expansion valued at USD7.7 million would improve the company's influence in the market.
Grandhope's successful listing depends on its technology and insight of the medical device industry market.
Grandhope mainly relies on its independent R&D to get into the medical device industry. Grandhope is a high-tech enterprise engaged in regenerative medical materials and medical implants development, production and sales. Because of Grandhope's independent R&D, it has developed a new type medical material made by cow's or pig's membranes, which belongs to the extracellular matrix material. Based on the technology of extracellular material, Grandhope's products develop epoxy tissue fixation technology, full antigen-technology and mechanics induced modification technology and organizational techniques to resolve the weakness of the traditional extracellular matrix material. Its product has the capability of high stability, low immunogenicity and tissue regeneration inducement which had their own advantages in the industry competition. Grandhope applied these to launch its products such as biotype hard brain membrane, general thoracic surgical repair membrane and sterile bio-protection membrane.
Extracellular matrix material, which will replace the conventional biomedical materials such as synthetical biomaterials and alloy materials, can adhere to the injury compatibly. By its function, it can replace the disease tissue's function during the cell regeneration. Furthermore, the cell regeneration can be induced by this material compared with the conventional biomedical materials, which just play a short term alternative role to the injury.
Grandhope is optimistic about its products' future prospects in domestic medical device market, especially in meningeal medical market. Grandhope gained great profit mainly from its brain membrane from 2006 to 2010. The products' actual quantity had been accumulated to100,000 till 2010 without medical negligence. Its biotype brain membrane, higher cost performance than the products from foreign enterprises, has occupied 43% ofChina Germany
Furthermore, Granhope will focus on R&D medical cosmetic surgery market in future although it has some difficulties in collaborative project with Renhe Group, this project will not be arranged in next three months.
Grandhope's insight into the global medical device industry leads the enterprise to focus on the extracellular matrix material's R&D in recent years. Owing to rapid expansion with the growth rate of 6% - 12% per year from 2006 to 2008, the global medical device industry is growing into the pillar industry of the global economy. In 2009, the production value of global medical device industry was over USD370 billion. More importantly, the output value ofChina China China 's surgical implant's market will become the second largest market after the market in the US
Grandhope has become the sixth listed biomedical enterprises in
The raised fund for Grandhope's IPO will be mainly applied to these investments: construction of regenerative medical implants national engineering laboratory, high-tech industrialization of sterile biological membrane, market expansion and maintenance of the core business. Mr. Zhu especially explained the strategy of the first three projects: the construction of the laboratory, which costs Grandhope USD5.9 million, would lead the company to strengthen the core competitiveness in the high-tech field. In order to get more profit and market share, Grandhope invested USD3.1 million in high-tech industrialization of sterile biological membrane, which would promote the adjustment of the product structure. The market expansion valued at USD7.7 million would improve the company's influence in the market.
Grandhope's successful listing depends on its technology and insight of the medical device industry market.
Grandhope mainly relies on its independent R&D to get into the medical device industry. Grandhope is a high-tech enterprise engaged in regenerative medical materials and medical implants development, production and sales. Because of Grandhope's independent R&D, it has developed a new type medical material made by cow's or pig's membranes, which belongs to the extracellular matrix material. Based on the technology of extracellular material, Grandhope's products develop epoxy tissue fixation technology, full antigen-technology and mechanics induced modification technology and organizational techniques to resolve the weakness of the traditional extracellular matrix material. Its product has the capability of high stability, low immunogenicity and tissue regeneration inducement which had their own advantages in the industry competition. Grandhope applied these to launch its products such as biotype hard brain membrane, general thoracic surgical repair membrane and sterile bio-protection membrane.
Extracellular matrix material, which will replace the conventional biomedical materials such as synthetical biomaterials and alloy materials, can adhere to the injury compatibly. By its function, it can replace the disease tissue's function during the cell regeneration. Furthermore, the cell regeneration can be induced by this material compared with the conventional biomedical materials, which just play a short term alternative role to the injury.
Grandhope is optimistic about its products' future prospects in domestic medical device market, especially in meningeal medical market. Grandhope gained great profit mainly from its brain membrane from 2006 to 2010. The products' actual quantity had been accumulated to100,000 till 2010 without medical negligence. Its biotype brain membrane, higher cost performance than the products from foreign enterprises, has occupied 43% of
Furthermore, Granhope will focus on R&D medical cosmetic surgery market in future although it has some difficulties in collaborative project with Renhe Group, this project will not be arranged in next three months.
Grandhope's insight into the global medical device industry leads the enterprise to focus on the extracellular matrix material's R&D in recent years. Owing to rapid expansion with the growth rate of 6% - 12% per year from 2006 to 2008, the global medical device industry is growing into the pillar industry of the global economy. In 2009, the production value of global medical device industry was over USD370 billion. More importantly, the output value of
Main content of Industrial Biotechnology China News 1108:
Shandong Jingdian to produce glycerin-based PG
Baosteel to promote industrialization of carbon monoxide-based fuel ethanol
Celanese to seize China's ethanol market
Trade analysis of China's butanol
Angel Yeast to accelerate its expansion of yeast capacity
Domestic hemicellulase investment increases greatly
CAS plans to accelerate its commercial production of SA
Rapid L-tryptophan expansion in China
Changjiang Chemical Fiber makes a breakthrough on industrialization of PLA fiber
RSPC to invest in PTT fiber
Wanwei Updated High-tech's PVA expansion
Trade analysis of China's PLA
Grandhope launches IPO in Shenzhen Growth Enterprise Market
Baosteel to promote industrialization of carbon monoxide-based fuel ethanol
Celanese to seize China's ethanol market
Trade analysis of China's butanol
Angel Yeast to accelerate its expansion of yeast capacity
Domestic hemicellulase investment increases greatly
CAS plans to accelerate its commercial production of SA
Rapid L-tryptophan expansion in China
Changjiang Chemical Fiber makes a breakthrough on industrialization of PLA fiber
RSPC to invest in PTT fiber
Wanwei Updated High-tech's PVA expansion
Trade analysis of China's PLA
Grandhope launches IPO in Shenzhen Growth Enterprise Market
Industrial Biotechnology China News, a monthly publication issued by CCM International on 8th of every month, focuses on biofuels, bio-products, bio-based chemicals, bio-materials and industrial biotechnology applications, offers latest investment hotspots, new technology & product, company & market dynamics, and government regulations, aiming to facilitate your insight into China's industrial biotechnology.
Please visit http://www.cnchemicals.com for more information or contact us at econtact@cnchemicals.com.
No comments:
Post a Comment